Essential Partners’s Telomir Pharmaceuticals TELO Stock Holding History

Essential Partners’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-63	Closed	-$79	–	2806
2025 Q2	$79	Buy	+63	New	+$146	﹤0.01%	2098

Other funds holding TELO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Essential Partners's TELO Position: Q3 2025 in Review

Essential Partners sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 63 shares — an estimated $79 sold.

Essential Partners first reported a position in TELO in Q2 2025 and held it in 1 quarter. The position peaked at $79 in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

Essential Partners reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 63 Telomir Pharmaceuticals shares in Q3 2025, an estimated $79.
Essential Partners first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Essential Partners's Telomir Pharmaceuticals position peaked at $79 in Q2 2025.
32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.